Creative Medical Technology (CELZ) Competitors

Creative Medical Technology logo
$0.47 -0.01 (-2.16%)
Closing price 04:00 PM Eastern
Extended Trading
$0.47 +0.00 (+0.15%)
As of 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CELZ vs. ATYR, NCEL, ABOS, APLT, and JSPR

Should you buy Creative Medical Technology stock or one of its competitors? Creative Medical Technology's main competitors and comparable companies include aTyr Pharma (ATYR), NLS Pharmaceutics (NCEL), Acumen Pharmaceuticals (ABOS), Applied Therapeutics (APLT), and Jasper Therapeutics (JSPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Creative Medical Technology compare to aTyr Pharma?

Creative Medical Technology (NASDAQ:CELZ) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Creative Medical Technology has a beta of 2.1, suggesting that its share price is 110% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

In the previous week, aTyr Pharma had 3 more articles in the media than Creative Medical Technology. MarketBeat recorded 4 mentions for aTyr Pharma and 1 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 1.65 beat aTyr Pharma's score of 0.22 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Creative Medical Technology
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
aTyr Pharma
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

aTyr Pharma has a consensus price target of $5.00, indicating a potential upside of 0.20%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Creative Medical Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creative Medical Technology
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
aTyr Pharma
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.33

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 13.8% of Creative Medical Technology shares are held by company insiders. Comparatively, 5.0% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Creative Medical Technology's return on equity of -101.97% beat aTyr Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Creative Medical TechnologyN/A -101.97% -96.74%
aTyr Pharma N/A -102.83%-70.56%

Creative Medical Technology has higher earnings, but lower revenue than aTyr Pharma. Creative Medical Technology is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creative Medical Technology$10K361.74-$5.99M-$1.99N/A
aTyr Pharma$190K66.97-$74.12M-$21.83N/A

Summary

Creative Medical Technology and aTyr Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Creative Medical Technology compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Creative Medical Technology has higher revenue and earnings than NLS Pharmaceutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NLS PharmaceuticsN/AN/A-$8.30MN/AN/A
Creative Medical Technology$10K361.74-$5.99M-$1.99N/A

NLS Pharmaceutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market.

NLS Pharmaceutics' return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
NLS PharmaceuticsN/A N/A N/A
Creative Medical Technology N/A -101.97%-96.74%

NLS Pharmaceutics presently has a consensus target price of $23.00, suggesting a potential upside of 758.21%. Given NLS Pharmaceutics' higher possible upside, analysts plainly believe NLS Pharmaceutics is more favorable than Creative Medical Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NLS Pharmaceutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Creative Medical Technology
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Creative Medical Technology had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for Creative Medical Technology and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.82 beat Creative Medical Technology's score of 1.65 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company Overall Sentiment
NLS Pharmaceutics Very Positive
Creative Medical Technology Very Positive

1.4% of Creative Medical Technology shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 13.8% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

NLS Pharmaceutics and Creative Medical Technology tied by winning 5 of the 10 factors compared between the two stocks.

How does Creative Medical Technology compare to Acumen Pharmaceuticals?

Creative Medical Technology (NASDAQ:CELZ) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Creative Medical Technology has higher revenue and earnings than Acumen Pharmaceuticals. Creative Medical Technology is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creative Medical Technology$10K361.74-$5.99M-$1.99N/A
Acumen PharmaceuticalsN/AN/A-$121.33M-$1.54N/A

Acumen Pharmaceuticals has a consensus price target of $1.00, suggesting a potential upside of 334.59%. Given Acumen Pharmaceuticals' higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Creative Medical Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creative Medical Technology
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Acumen Pharmaceuticals
3 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.71

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 13.8% of Creative Medical Technology shares are owned by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Creative Medical Technology's return on equity of -101.97% beat Acumen Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Creative Medical TechnologyN/A -101.97% -96.74%
Acumen Pharmaceuticals N/A -166.49%-90.79%

In the previous week, Creative Medical Technology had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 1 mentions for Creative Medical Technology and 0 mentions for Acumen Pharmaceuticals. Creative Medical Technology's average media sentiment score of 1.65 beat Acumen Pharmaceuticals' score of 0.41 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company Overall Sentiment
Creative Medical Technology Very Positive
Acumen Pharmaceuticals Neutral

Creative Medical Technology has a beta of 2.1, meaning that its stock price is 110% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Summary

Creative Medical Technology beats Acumen Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Creative Medical Technology compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Applied Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market.

Applied Therapeutics presently has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' higher probable upside, equities analysts plainly believe Applied Therapeutics is more favorable than Creative Medical Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Creative Medical Technology
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Creative Medical Technology has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Therapeutics$1M15.86-$105.62M-$0.10N/A
Creative Medical Technology$10K361.74-$5.99M-$1.99N/A

Creative Medical Technology's return on equity of -101.97% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Applied TherapeuticsN/A -340.84% -175.00%
Creative Medical Technology N/A -101.97%-96.74%

In the previous week, Creative Medical Technology had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for Creative Medical Technology and 0 mentions for Applied Therapeutics. Creative Medical Technology's average media sentiment score of 1.65 beat Applied Therapeutics' score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company Overall Sentiment
Applied Therapeutics Neutral
Creative Medical Technology Very Positive

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 13.8% of Creative Medical Technology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Creative Medical Technology beats Applied Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Creative Medical Technology compare to Jasper Therapeutics?

Creative Medical Technology (NASDAQ:CELZ) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Jasper Therapeutics has a consensus target price of $220.00, suggesting a potential upside of 2,027.66%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than Creative Medical Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creative Medical Technology
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Jasper Therapeutics
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38

Creative Medical Technology has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.3, indicating that its stock price is 230% more volatile than the broader market.

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 13.8% of Creative Medical Technology shares are owned by company insiders. Comparatively, 3.9% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Creative Medical Technology has higher revenue and earnings than Jasper Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creative Medical Technology$10K361.74-$5.99M-$1.99N/A
Jasper TherapeuticsN/AN/A-$75.80M-$47.75N/A

Creative Medical Technology's return on equity of -101.97% beat Jasper Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Creative Medical TechnologyN/A -101.97% -96.74%
Jasper Therapeutics N/A -1,392.77%-181.56%

In the previous week, Jasper Therapeutics had 5 more articles in the media than Creative Medical Technology. MarketBeat recorded 6 mentions for Jasper Therapeutics and 1 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 1.65 beat Jasper Therapeutics' score of 0.06 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Creative Medical Technology
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Jasper Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Creative Medical Technology beats Jasper Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Creative Medical Technology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CELZ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CELZ vs. The Competition

MetricCreative Medical TechnologyBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.62M$4.03B$7.72B$11.68B
Dividend YieldN/A3.63%2.47%4.51%
P/E RatioN/A25.9032.4827.27
Price / Sales353.9215.668.385.63
Price / CashN/A22.7220.8521.62
Price / Book0.514.164.443.72
Net Income-$5.99M-$23.99M$3.51B$394.03M
7 Day Performance-25.95%-8.45%-6.54%-6.07%
1 Month Performance-37.07%-6.55%-4.93%-7.38%
1 Year Performance-84.71%-6.56%-1.68%-7.46%

Creative Medical Technology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CELZ
Creative Medical Technology
1.7343 of 5 stars
$0.47
-2.2%
N/A-84.4%$3.62M$10KN/A4
ATYR
aTyr Pharma
3.0976 of 5 stars
$6.45
-4.8%
$5.00
-22.4%
-81.7%$16.43MN/AN/A58
NCEL
NLS Pharmaceutics
1.6229 of 5 stars
$2.77
-1.1%
$23.00
+730.3%
-23.0%$16MN/AN/A6
ABOS
Acumen Pharmaceuticals
2.6526 of 5 stars
$0.22
-4.3%
$1.00
+354.5%
-85.4%$15.91MN/AN/A61
APLT
Applied Therapeutics
N/A$0.10
flat
$1.00
+870.9%
N/A$15.86M$1MN/A30

Related Companies and Tools


This page (NASDAQ:CELZ) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners